The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Mar 2016
Randomized Controlled Trial Multicenter Study Comparative StudySafety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity. Combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab might provide greater antitumour activity than either drug alone. We aimed to assess durvalumab plus tremelimumab in patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC). ⋯ MedImmune.
-
The lancet oncology · Mar 2016
Randomized Controlled Trial Comparative StudyBenefits of pazopanib over sunitinib for renal cell carcinoma.